Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $3.64B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $5.19M in total
- 6
- 13F holdersQ2 2026, +4 vs. previous quarter
- 256
- 13F valueReported value at the end of Q2 2026
- $2.98B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $451.4M
- +146.7% year over year
- Net income, FY2025
- -$66.4M
- No comparable prior period
- Free cash flow, FY2025
- -$22.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $194.6M
- +63.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $66.4M (14.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.07M
- Shares sold short
- Change
- +335.1K
- +5.9% vs. previous
- Days to cover
- 6.94
- At average daily volume
Superinvestors holding TARS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TARS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Tarsus Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:22 PM ET | Sep 15 | 2 days | Link William J PhDDirector | SSale | −12.5K | $78.38 | −$979.7K | −11.7%94.5K after | 3 lots10b5-1 |
| Sep 9, 2026 (view filing)4:14 PM ET | Sep 4 | 5 days | Azamian Bobak R.President/CEO and Board Chair | SSale | −10.0K | $90.56 | −$905.6K | −1.2%828.0K after | 2 lots10b5-1 |
| Sep 9, 2026 (view filing)4:13 PM ET | Sep 4 | 5 days | Lin Elizabeth YeuChief Medical Officer | SSale | −10.8K | $87.50 | −$942.6K | −80.9%2.55K after | 2 lots10b5-1 |
| Sep 9, 2026 (view filing)4:13 PM ET | Sep 4 | 5 days | Lin Elizabeth YeuChief Medical Officer | SSale | −3.18K | $87.50 | −$278.3K | −66.7%1.59K after | 2 lots10b5-1 |
| Sep 9, 2026 (view filing)4:12 PM ET | Sep 4 | 5 days | Neervannan SeshadriChief Operating Officer | SSale | −4.56K | $85.00 | −$387.9K | −5.5%78.5K after | 10b5-1 |
| Sep 3, 2026 (view filing)4:30 PM ET | Sep 2 | 1 day | Azamian Bobak R.President/CEO and Board Chair | SSale | −10.0K | $80.06 | −$800.6K | −1.2%838.0K after | 10b5-1 |
| Sep 3, 2026 (view filing)4:29 PM ET | Sep 1-2 | 2 days | Lin Elizabeth YeuChief Medical Officer | SSale | −9.99K | $77.17 | −$770.8K | −42.9%13.3K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:29 PM ET | Sep 2 | 1 day | Lin Elizabeth YeuChief Medical Officer | SSale | −1.59K | $80.00 | −$127.2K | −25.0%4.77K after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Azamian Bobak R.President/CEO and Board Chair | SSale | −10.0K | $61.55 | −$615.5K | −1.2%848.0K after | 2 lots10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Goodrich KatherineDirector | SSale | −2.95K | $62.08 | −$183.4K | −57.0%2.23K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 256 holdersThe largest institutional positions in Tarsus Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,856,137 | $242.7M | 0.00% | +303,525+8.5% | Added |
| Deep Track Capital, LP | 3,666,768 | $230.8M | 3.40% | +66,768+1.9% | Added |
| RTW Investments, LP | 3,357,059 | $211.3M | 1.80% | +11,034+0.3% | Added |
| Jupiter Topco LLC | 2,808,796 | $176.8M | 0.07% | +2,808,796 | New |
| Paradigm Biocapital Advisors LP | 2,775,649 | $174.7M | 3.27% | +213,495+8.3% | Added |
| Morgan Stanley | 1,827,082 | $115.0M | 0.01% | −117,190−6.0% | Reduced |
| Vanguard Capital Management LLC | 1,793,064 | $112.9M | 0.00% | +32,523+1.8% | Added |
| Jennison Associates LLC | 1,663,655 | $104.7M | 0.06% | −48,469−2.8% | Reduced |
| Tang Capital Management LLC | 1,568,266 | $98.7M | 4.48% | +379,642+31.9% | Added |
| Millennium Management LLC | 1,427,124 | $89.8M | 0.06% | +862,545+152.8% | Added |
Holders of 5% or more of TARS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Tarsus Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 13G/A | 8.46%3.60M shares | +1.35 ppfrom 7.11% | Jul 28, 20253 filings | May 15, 2026 | SEC |
| RTW Investments, LP | 13G/A | 8.10%3.42M shares | – | Feb 12, 20215 filings | Aug 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.40%3.09M shares | – | Oct 21, 20243 filings | Apr 24, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 6.50%2.81M shares | +1.20 ppfrom 5.30% | May 15, 20262 filings | Aug 13, 2026 | SEC |
| FMR LLC | 13G | 6.40%3.14M shares | New | Nov 5, 20261 filing | Nov 5, 2026 | SEC |